One of the most common drivers in human cancer is the mutant KRAS protein. Not so long
ago KRAS was considered as an undruggable oncoprotein. After a long struggle, however …

RAS has long been viewed as undruggable due to its lack of deep pockets for binding of
small molecule inhibitors. However, recent successes in the development of direct RAS …

Tumour-associated KRAS mutations are the most prevalent in the three RAS-family isoforms
and involve many different amino-acids. Therefore, molecules able to interfere with mutant …

The RAS gene family is frequently mutated in human cancers, and the quest for compounds
that bind to mutant RAS remains a major goal, as it also does for inhibitors of protein–protein …

Targeting specific protein–protein interactions (PPIs) is an attractive concept for drug
development, but hard to implement since intracellular antibodies do not penetrate cells and …

RAS is the most frequently mutated oncogene in cancer and a critical driver of oncogenesis.
Therapeutic targeting of RAS has been a goal of cancer research for more than 30 years …

Inhibiting the RAS oncogenic protein has largely been through targeting the switch regions
that interact with signalling effector proteins. Here, we report designed ankyrin repeat …

Since its discovery as an oncogene more than 40 years ago, Ras has been and still is in the
focus of many academic and pharmaceutical labs around the world. A huge amount of work …

RAS drug development has made enormous strides in the past ten years, with the first direct
KRAS inhibitor being approved in 2021. However, despite the clinical success of covalent …

The small GTPase Ras is a critical regulator of cell growth and proliferation. Its activity is
frequently dysregulated in cancers, prompting decades of work to pharmacologically target …